Single-Session Percutaneous Mechanical Thrombectomy Using the Aspirex(R)S Device Plus Stenting for Acute Iliofemoral Deep Vein Thrombosis: Safety, Efficacy, and Mid-Term Outcomes

To assess the safety, efficacy and mid-term outcomes of single-session percutaneous mechanical thrombectomy (PMT) for acute symptomatic iliofemoral deep vein thrombosis (DVT) using the Aspirex(R)S device. Retrospective review of 30 patients (women, 23; mean age, 45.5 +/- 19.9 years; range, 17-76) who underwent PMT with the 10-French Aspirex(R)S device (Straub Medical AG, Wangs, Switzerland) for acute DVT between December 2015 and March 2019. Procedures were performed by popliteal (n= 22) or jugular (n= 7) approach, or both (n= 1). Mean time from diagnosis to PMT was 5.5 +/- 4.6 days (range, 2-11). Successful thrombus removal and venous patency restoration were achieved in all patients (100%). Fluid removal was 307.8 +/- 66.1 mL (range, 190-410). Additional venous stenting rate was 100%. Mean procedural time was 107.3 +/- 33.9 min (range, 70-180). No major complication occurred. The patient's postprocedural course was uneventful in all cases, with hospital discharge within 2 days in 83.3%. Early in-stent rethrombosis occurred within 1 week in 3 patients, successfully managed by endovascular approach. Secondary stent patency rate was 86.7% at a mean follow-up of 22.3 +/- 14.2 months (range, 6-48), as assessed by Duplex ultrasound. Single-session of PMT using the Aspirex(R)S device is a safe and effective therapeutic option in patients presenting with acute symptomatic iliofemoral DVT.